Scarica l'app Stockscreener
19.95
0.30%
0.06
Dopo l'orario di chiusura:
19.89
-0.06
-0.30%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ACAD Giù?
Forum
Previsione
Acadia Pharmaceuticals Inc Borsa (ACAD) Ultime notizie
Acadia Pharmaceuticals stock hits 52-week low at $19.66 - Investing.com India
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc.ACAD - PR Newswire
ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo Finance
Acadia Pharmaceuticals Inc. (ACAD) Stock Price, News, Quote & History - Yahoo! Finance Canada
ACADIA Pharmaceuticals Inc. (ACAD) Stock forecasts - Yahoo Finance Australia
How (ACAD) Movements Inform Risk Allocation Models - Stock Traders Daily
Acadia Pharmaceuticals Inc. (ACAD) stock price, news, quote and history - uk.finance.yahoo.com
Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041 - Yahoo Finance
Acadia debuts 63,000 sq. ft. Princeton office, biopharma hub designed by Ware Malcomb - Real Estate NJ
Acadia Pharmaceuticals (ACAD) Secures USPTO Notice of Allowance for Rett Syndrome Patent - GuruFocus
Acadia Pharmaceuticals Gets US Patent Office Allowance for Trofinetide Dosing Patent - Yahoo Finance
Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041 - Yahoo Finance
Acadia Pharmaceuticals stock price target lowered to $33 by H.C. Wainwright - Investing.com Canada
Acadia Pharmaceuticals (ACAD) Stock Trades At A Discount After A 29% Drop - Yahoo Finance
Acadia Pharmaceuticals (ACAD) Stock May Be Mispriced After Mixed Phase III Push - Simply Wall Street
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP) - 기업경제뉴스
Acadia Pharmaceuticals (ACAD) Shares Drop After Phase 2 RADIANT Study Results - GuruFocus
Acadia Pharmaceuticals drops 7%, continuing fall after drug trial results (ACAD:NASDAQ) - Seeking Alpha
Acadia push in ADP still alive after near miss in phase II - BioWorld News
Acadia Pharmaceuticals' Risk-Reward Favorable After Remlifanserin Data, Deutsche Bank Says - Yahoo Finance
ACAD Maintains Buy Rating -- Price Target Lowered to $33.00 by HC Wainwright - GuruFocus
ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal - Yahoo Finance
Acadia chugs on with Alzheimer’s psychosis programme despite Phase II miss - Yahoo Finance
ACADIA Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co. - Moomoo
HC Wainwright & Co. maintains Buy rating on ACADIA Pharmaceuticals, $33 price target - TradingView
Needham cuts Acadia Pharmaceuticals stock price target on trial results By Investing.com - Investing.com Nigeria
Citizens maintains Market Outperform rating on ACADIA Pharmaceuticals, $33 price target - TradingView
Needham cuts Acadia Pharmaceuticals stock price target on trial results - Investing.com
ACAD Maintained by Needham -- Price Target Lowered to $35 - GuruFocus
Deutsche Bank Lowers Price Target on ACADIA Pharmaceuticals to $31 From $38, Keeps Buy Rating - Yahoo Finance
Citizens cuts Acadia Pharmaceuticals stock price target on trial miss By Investing.com - Investing.com Canada
Ware Malcomb says construction finished on Acadia Pharmaceuticals’ Princeton office - ROI-NJ
ACADIA Pharmaceuticals (ACAD) Gets ‘Sell’ Rating on Weak Trial Results, Shares Fall 13% - Yahoo Finance
Acadia Pharmaceuticals stock tumbles on mixed trial results - Investing.com
Acadia Pharmaceuticals Fell 19% Today. Here’s Where the Stock Could Go in 2026 - TIKR.com
Acadia Alters Phase III Trials To Help Remlifanserin Succeed In Alzheimer’s Psychosis - insights.citeline.com
ACAD Stock Clocks Worst Day In 2 Years After Alzheimer’s Psychosis Drug Misses Main Goal — Citi Cuts Drug’s Success Odds To 20% - Yahoo Finance
Acadia Reports Phase 2 Data for Alzheimer’s Psychosis - TipRanks
Acadia reports Phase 3-enabling Phase 2 topline for remlifanserin in AD psychosis; 60 mg shows nominal CGI-S significance - TradingView
Biotech Rattled On Surprise Setback For Alzheimer's Drug - Investor's Business Daily
ACADIA Pharmaceuticals (ACAD) Drops 8.6% to $23.25 - AlphaStreet
BMO cuts Acadia Pharmaceuticals stock price target on trial miss By Investing.com - Investing.com Australia
ACADIA Pharma's price target cut after mixed Al... - Pluang
Goldman Sachs reiterates Acadia Pharmaceuticals stock Sell rating after trial miss - Investing.com Canada
TD Cowen reiterates Acadia Pharmaceuticals stock rating on trial data By Investing.com - Investing.com Canada
ACADIA Pharmaceuticals Inc. (ACAD) Discusses Top-Line Phase II Results From RADIANT Study of Remlifanserin in Alzheimer's Disease PsychosisSlideshow (NASDAQ:ACAD) 2026-09-24 - Seeking Alpha
Why Is Acadia Pharmaceuticals Stock Tumbling Today?ACADIA Pharmaceuticals (NASDAQ:ACAD) - benzinga.com
BMO cuts Acadia Pharmaceuticals stock price target on trial miss - Investing.com
Remlifanserin misses key goal in Alzheimer’s tr... - Pluang
Acadia shares drop 9% after mixed Phase 2 resul... - Pluang
Acadia Pharmaceuticals: Remlifanserin Is In Trouble (NASDAQ:ACAD) - Seeking Alpha
ACADIA Pharmaceuticals (ACAD) Reiterated by Needham -- Price Tar - GuruFocus
Acadia's Alzheimer's psychosis drug remlifanserin posts Phase 3-enabling Phase 2 results - Dealroom.co
Acadia Pharmaceuticals shares slide on mixed Alzheimer's psychosis data - Yahoo Finance
ACADIA Advances 60 mg Remlifanserin After Near-Miss in Alzheimer’s Psychosis Trial - TradingView
Acadia drug fails mid-stage study in Alzheimer’s psychosis, leading to modified Phase 3 - Endpoints News
Acadia slides on Phase 2 miss in Alzheimer’s psychosis but keeps moving asset forward - biospace.com
Why is ACADIA Pharmaceuticals stock tumbling today? By Investing.com - Investing.com Canada
Acadia Pharmaceuticals Shares Fall After RADIANT Phase 2 Study Misses Primary Endpoint - Yahoo Finance
Acadia misses mark in Alzheimer’s but concludes phase 3 ‘absolutely worth’ pursuing - Fierce Biotech
Sector Update: Healthcare Stocks Mixed Pre-Bell Thursday - Yahoo Finance
Acadia falls after mid-stage trial setback for Alzheimer’s psychosis therapy - TradingView
Why is ACADIA Pharmaceuticals stock sliding today? By Investing.com - Investing.com Canada
Acadia's Alzheimer's psychosis drug misses main goal of mid-stage study - marketscreener.com
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):